Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Recurrent Glioblastoma Multiforme Treatment market report explains the definition, types, applications, major countries, and major players of the Recurrent Glioblastoma Multiforme Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
ERC Belgium SA
Cortice Biosciences Inc
Cantex Pharmaceuticals Inc
Eisai
Cavion LLC
Boston Biomedical Inc
Genzyme Corporation
GW Pharmaceuticals Plc
Bristol-Myers Squibb Company
Coherus BioSciences Inc
Boehringer Ingelheim GmbH
Celldex Therapeutics Inc
GenSpera Inc
ImmunoCellular Therapeutics Ltd
Eli Lilly and Company
EnGeneIC Ltd
By Type:
AU-105
Axitinib
AXL-1717
AZD-7451
Others
By End-User:
Hospital
Clinic
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Recurrent Glioblastoma Multiforme Treatment Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Recurrent Glioblastoma Multiforme Treatment Outlook to 2028- Original Forecasts
-
2.2 Recurrent Glioblastoma Multiforme Treatment Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Recurrent Glioblastoma Multiforme Treatment Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Recurrent Glioblastoma Multiforme Treatment Market- Recent Developments
-
6.1 Recurrent Glioblastoma Multiforme Treatment Market News and Developments
-
6.2 Recurrent Glioblastoma Multiforme Treatment Market Deals Landscape
7 Recurrent Glioblastoma Multiforme Treatment Raw Materials and Cost Structure Analysis
-
7.1 Recurrent Glioblastoma Multiforme Treatment Key Raw Materials
-
7.2 Recurrent Glioblastoma Multiforme Treatment Price Trend of Key Raw Materials
-
7.3 Recurrent Glioblastoma Multiforme Treatment Key Suppliers of Raw Materials
-
7.4 Recurrent Glioblastoma Multiforme Treatment Market Concentration Rate of Raw Materials
-
7.5 Recurrent Glioblastoma Multiforme Treatment Cost Structure Analysis
-
7.5.1 Recurrent Glioblastoma Multiforme Treatment Raw Materials Analysis
-
7.5.2 Recurrent Glioblastoma Multiforme Treatment Labor Cost Analysis
-
7.5.3 Recurrent Glioblastoma Multiforme Treatment Manufacturing Expenses Analysis
8 Global Recurrent Glioblastoma Multiforme Treatment Import and Export Analysis (Top 10 Countries)
-
8.1 Global Recurrent Glioblastoma Multiforme Treatment Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Recurrent Glioblastoma Multiforme Treatment Export by Region (Top 10 Countries) (2017-2028)
9 Global Recurrent Glioblastoma Multiforme Treatment Market Outlook by Types and Applications to 2022
-
9.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global AU-105 Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Axitinib Consumption and Growth Rate (2017-2022)
-
9.1.3 Global AXL-1717 Consumption and Growth Rate (2017-2022)
-
9.1.4 Global AZD-7451 Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Recurrent Glioblastoma Multiforme Treatment Market Analysis and Outlook till 2022
-
10.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.2.2 Canada Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.2.3 Mexico Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.2 UK Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.3 Spain Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.4 Belgium Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.5 France Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.6 Italy Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.7 Denmark Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.8 Finland Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.9 Norway Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.10 Sweden Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.11 Poland Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.12 Russia Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.3.13 Turkey Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.2 Japan Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.3 India Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.4 South Korea Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.5 Pakistan Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.6 Bangladesh Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.7 Indonesia Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.8 Thailand Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.9 Singapore Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.10 Malaysia Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.11 Philippines Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.4.12 Vietnam Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.5.2 Colombia Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.5.3 Chile Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.5.4 Argentina Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.5.5 Venezuela Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.5.6 Peru Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.5.7 Puerto Rico Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.5.8 Ecuador Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.6.2 Kuwait Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.6.3 Oman Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.6.4 Qatar Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.6.5 Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.6.6 United Arab Emirates Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.7.2 South Africa Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.7.3 Egypt Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.7.4 Algeria Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
-
10.8.2 New Zealand Recurrent Glioblastoma Multiforme Treatment Consumption (2017-2022)
11 Global Recurrent Glioblastoma Multiforme Treatment Competitive Analysis
-
11.1 ERC Belgium SA
-
11.1.1 ERC Belgium SA Company Details
-
11.1.2 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.1.4 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Cortice Biosciences Inc
-
11.2.1 Cortice Biosciences Inc Company Details
-
11.2.2 Cortice Biosciences Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Cortice Biosciences Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.2.4 Cortice Biosciences Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Cantex Pharmaceuticals Inc
-
11.3.1 Cantex Pharmaceuticals Inc Company Details
-
11.3.2 Cantex Pharmaceuticals Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Cantex Pharmaceuticals Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.3.4 Cantex Pharmaceuticals Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Eisai
-
11.4.1 Eisai Company Details
-
11.4.2 Eisai Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Eisai Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.4.4 Eisai Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Cavion LLC
-
11.5.1 Cavion LLC Company Details
-
11.5.2 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.5.4 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Boston Biomedical Inc
-
11.6.1 Boston Biomedical Inc Company Details
-
11.6.2 Boston Biomedical Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Boston Biomedical Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.6.4 Boston Biomedical Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Genzyme Corporation
-
11.7.1 Genzyme Corporation Company Details
-
11.7.2 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.7.4 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 GW Pharmaceuticals Plc
-
11.8.1 GW Pharmaceuticals Plc Company Details
-
11.8.2 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.8.4 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Bristol-Myers Squibb Company
-
11.9.1 Bristol-Myers Squibb Company Company Details
-
11.9.2 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.9.4 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Coherus BioSciences Inc
-
11.10.1 Coherus BioSciences Inc Company Details
-
11.10.2 Coherus BioSciences Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Coherus BioSciences Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.10.4 Coherus BioSciences Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Boehringer Ingelheim GmbH
-
11.11.1 Boehringer Ingelheim GmbH Company Details
-
11.11.2 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.11.4 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Celldex Therapeutics Inc
-
11.12.1 Celldex Therapeutics Inc Company Details
-
11.12.2 Celldex Therapeutics Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Celldex Therapeutics Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.12.4 Celldex Therapeutics Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 GenSpera Inc
-
11.13.1 GenSpera Inc Company Details
-
11.13.2 GenSpera Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 GenSpera Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.13.4 GenSpera Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 ImmunoCellular Therapeutics Ltd
-
11.14.1 ImmunoCellular Therapeutics Ltd Company Details
-
11.14.2 ImmunoCellular Therapeutics Ltd Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 ImmunoCellular Therapeutics Ltd Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.14.4 ImmunoCellular Therapeutics Ltd Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Eli Lilly and Company
-
11.15.1 Eli Lilly and Company Company Details
-
11.15.2 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.15.4 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 EnGeneIC Ltd
-
11.16.1 EnGeneIC Ltd Company Details
-
11.16.2 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
11.16.4 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
11.16.5 Recent Research and Development Strategies
12 Global Recurrent Glioblastoma Multiforme Treatment Market Outlook by Types and Applications to 2028
-
12.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global AU-105 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Axitinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global AXL-1717 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global AZD-7451 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Recurrent Glioblastoma Multiforme Treatment Market Analysis and Outlook to 2028
-
13.1 Global Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.2.2 Canada Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.2.3 Mexico Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.2 UK Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.3 Spain Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.4 Belgium Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.5 France Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.6 Italy Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.7 Denmark Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.8 Finland Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.9 Norway Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.10 Sweden Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.11 Poland Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.12 Russia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.3.13 Turkey Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.2 Japan Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.3 India Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.4 South Korea Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.8 Thailand Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.9 Singapore Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.11 Philippines Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.5.2 Colombia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.5.3 Chile Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.5.4 Argentina Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.5.6 Peru Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.6.3 Oman Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.6.4 Qatar Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.7.2 South Africa Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.7.3 Egypt Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.7.4 Algeria Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Recurrent Glioblastoma Multiforme Treatment Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Recurrent Glioblastoma Multiforme Treatment
-
Figure of Recurrent Glioblastoma Multiforme Treatment Picture
-
Table Global Recurrent Glioblastoma Multiforme Treatment Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Recurrent Glioblastoma Multiforme Treatment Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global AU-105 Consumption and Growth Rate (2017-2022)
-
Figure Global Axitinib Consumption and Growth Rate (2017-2022)
-
Figure Global AXL-1717 Consumption and Growth Rate (2017-2022)
-
Figure Global AZD-7451 Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Recurrent Glioblastoma Multiforme Treatment Consumption by Country (2017-2022)
-
Table North America Recurrent Glioblastoma Multiforme Treatment Consumption by Country (2017-2022)
-
Figure United States Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Canada Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Mexico Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Table Europe Recurrent Glioblastoma Multiforme Treatment Consumption by Country (2017-2022)
-
Figure Germany Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure UK Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Spain Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Belgium Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure France Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Italy Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Denmark Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Finland Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Norway Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Sweden Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Poland Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Russia Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Turkey Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Table APAC Recurrent Glioblastoma Multiforme Treatment Consumption by Country (2017-2022)
-
Figure China Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Japan Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure India Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Korea Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Thailand Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Singapore Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Philippines Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Table South America Recurrent Glioblastoma Multiforme Treatment Consumption by Country (2017-2022)
-
Figure Brazil Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Colombia Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Chile Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Argentina Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Peru Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Table GCC Recurrent Glioblastoma Multiforme Treatment Consumption by Country (2017-2022)
-
Figure Bahrain Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Oman Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Qatar Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Table Africa Recurrent Glioblastoma Multiforme Treatment Consumption by Country (2017-2022)
-
Figure Nigeria Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Africa Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Egypt Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure Algeria Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Table Oceania Recurrent Glioblastoma Multiforme Treatment Consumption by Country (2017-2022)
-
Figure Australia Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Recurrent Glioblastoma Multiforme Treatment Consumption and Growth Rate (2017-2022)
-
Table ERC Belgium SA Company Details
-
Table ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Cortice Biosciences Inc Company Details
-
Table Cortice Biosciences Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cortice Biosciences Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Cortice Biosciences Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Cantex Pharmaceuticals Inc Company Details
-
Table Cantex Pharmaceuticals Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cantex Pharmaceuticals Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Cantex Pharmaceuticals Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Eisai Company Details
-
Table Eisai Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eisai Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Eisai Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Cavion LLC Company Details
-
Table Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cavion LLC Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Boston Biomedical Inc Company Details
-
Table Boston Biomedical Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boston Biomedical Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Boston Biomedical Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Genzyme Corporation Company Details
-
Table Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table GW Pharmaceuticals Plc Company Details
-
Table GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Bristol-Myers Squibb Company Company Details
-
Table Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Coherus BioSciences Inc Company Details
-
Table Coherus BioSciences Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Coherus BioSciences Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Coherus BioSciences Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Boehringer Ingelheim GmbH Company Details
-
Table Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Celldex Therapeutics Inc Company Details
-
Table Celldex Therapeutics Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celldex Therapeutics Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Celldex Therapeutics Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table GenSpera Inc Company Details
-
Table GenSpera Inc Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table GenSpera Inc Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table GenSpera Inc Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table ImmunoCellular Therapeutics Ltd Company Details
-
Table ImmunoCellular Therapeutics Ltd Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table ImmunoCellular Therapeutics Ltd Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table ImmunoCellular Therapeutics Ltd Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table Eli Lilly and Company Company Details
-
Table Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Table EnGeneIC Ltd Company Details
-
Table EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Main Business and Markets Served
-
Table EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product Portfolio
-
Figure Global AU-105 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Axitinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global AXL-1717 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global AZD-7451 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Country (2022-2028)
-
Table North America Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Country (2022-2028)
-
Figure United States Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Country (2022-2028)
-
Figure Germany Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Country (2022-2028)
-
Figure China Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Country (2022-2028)
-
Figure Brazil Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Recurrent Glioblastoma Multiforme Treatment Consumption Forecast by Country (2022-2028)
-
Figure Australia Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Recurrent Glioblastoma Multiforme Treatment Consumption Forecast and Growth Rate (2022-2028)
-
